eMedicine Specialties > Obstetrics and Gynecology > Obstetrical Complications

Eclampsia: Follow-up

Author: Michael G Ross, MD, MPH, Professor of Obstetrics and Gynecology, David Geffen School of Medicine, University of California at Los Angeles; Professor, Department of Community Health Sciences, University of California at Los Angeles School of Public Health; Chair, Department of Obstetrics and Gynecology, Harbor-UCLA Medical Center
Contributor Information and Disclosures

Updated: Apr 1, 2009

Follow-up

Further Inpatient Care

Continue to monitor blood pressure, neurologic status, and urine output until the patient is stable after delivery. Patients may require antihypertensive therapy after delivery and hospital discharge.

Further Outpatient Care

Follow up 1-2 weeks after delivery to evaluate for blood pressure control and any residual deficits from the eclamptic seizure. Patients with persistent hypertension past 8 weeks' puerperium or neurologic changes may need medical referral.

Inpatient & Outpatient Medications

This disease is treated on an inpatient basis, as described above. Outpatient care plays no role in management.

Transfer

Eclampsia clearly poses a risk of considerable maternal and neonatal morbidity and mortality. Patients with eclampsia may benefit from management at a tertiary care center.

Deterrence/Prevention

  • Routine prenatal care
  • Early diagnosis and aggressive management of preeclampsia

Complications

  • As many as 56% of patients with eclampsia may have transient deficits, including cortical blindness.
  • Studies have failed to demonstrate evidence of persisting neurologic deficits after uncomplicated eclamptic seizures during the follow-up period.6
  • Maternal, as well as fetal, death can be a consequence of eclampsia and its complications.

Prognosis

  • About 25% of women with eclampsia have hypertension in subsequent pregnancies.
  • 5% of patients with hypertension develop severe preeclampsia.
  • About 2% of women with eclampsia develop eclampsia with future pregnancies.
  • Multiparous women with eclampsia have the following:
    • A higher risk for development of essential hypertension
    • A higher mortality rate in subsequent pregnancies as compared with primiparous women

Patient Education

  • The patient should be advised and educated on the course of the disease and any residual problems.
  • The patient should be educated on the importance of adequate prenatal care in subsequent pregnancies.
  • If the patient has preexisting hypertension, she should have good control prior to conception and throughout pregnancy. Her case should be followed for recognition and treatment of preeclampsia.

Miscellaneous

Medicolegal Pitfalls

  • The mode of delivery should be based on obstetric indications, with the understanding that vaginal delivery is preferable from a maternal standpoint.
  • When emergent cesarean delivery is indicated, substantiating the absence of DIC prior to the procedure is important.
  • Fetal bradycardia is common following an eclamptic seizure and usually resolves within 10 minutes. Consider placental abruption if uterine hyperactivity remains and fetal bradycardia persists.
  • Cervical examination should not be overlooked. The delivery mode may be largely dependent on the cervical status.
  • Fluid management is critical in patients with eclampsia.
  • Avoid the use of multiple agents, unless necessary, to abate eclamptic seizures.
  • Ruling out eclampsia in an obstetrical patient who has been involved in an unexplained trauma is important.

Special Concerns

  • Do not overlook other neurologic causes, particularly if the seizure occurs more than 24 hours after delivery.
  • When preeclampsia occurs in the early second trimester (ie, 14-20 weeks' gestation), the diagnosis of hydatiform mole or choriocarcinoma should be considered.
  • Eclampsia always should be considered in a pregnant patient with a seizure episode.
  • A pregnant patient who has been involved in an unexplained trauma (such as a single-vehicle auto accident) and has exhibited seizure activity should be evaluated for eclampsia.
 
Acknowledgments

The authors and editors of eMedicine gratefully acknowledge the contributions of previous authors Stephanie R Fugate, DO and coauthor Gregory E Chow, MD to the development and writing of this article.



More on Eclampsia

Overview: Eclampsia
Differential Diagnoses & Workup: Eclampsia
Treatment & Medication: Eclampsia
Follow-up: Eclampsia
References

References

  1. Douglas KA, Redman CW. Eclampsia in the United Kingdom. BMJ. Nov 26 1994;309(6966):1395-400. [Medline].

  2. Mattar, F, Sibai BM. Eclampsia. VIII. Risk Factors for maternal morbidity. Am J Obstet Gynecol. 1990;163:1049-55.

  3. Zhang J, Meikle S, Trumble A. Severe maternal morbidity associated with hypertensive disorders in pregnancy in the United States. Hypertens Pregnancy. 2003;22(2):203-12. [Medline].

  4. Sahin, G. Incidence, morbidity and mortality of pre-eclampsia and eclampsia. Available at www.gfmer.ch/Endo/Course2003/eclampsia.htm. Accessed February 18, 2009.

  5. Sibai BM. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol. Feb 2005;105(2):402-10. [Medline].

  6. Sibai BM, Sarinoglu C, Mercer BM. Eclampsia. VII. Pregnancy outcome after eclampsia and long-term prognosis. Am J Obstet Gynecol. Jun 1992;166(6 Pt 1):1757-61; discussion 1761-3. [Medline].

  7. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol. Apr 2001;97(4):533-8. [Medline].

  8. Lucas MJ, Leveno KJ, Cunningham FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med. Jul 27 1995;333(4):201-5. [Medline].

Further Reading

Keywords

eclampsia, seizures in pregnancy, toxemia of pregnancy, coma in pregnancy, preeclampsia, cerebral vasospasm, focal ischemia, hypertensive encephalopathy

Contributor Information and Disclosures

Author

Michael G Ross, MD, MPH, Professor of Obstetrics and Gynecology, David Geffen School of Medicine, University of California at Los Angeles; Professor, Department of Community Health Sciences, University of California at Los Angeles School of Public Health; Chair, Department of Obstetrics and Gynecology, Harbor-UCLA Medical Center
Michael G Ross, MD, MPH is a member of the following medical societies: American Association for the Advancement of Science, American College of Obstetricians and Gynecologists, American Federation for Clinical Research, American Gynecological and Obstetrical Society, American Physiological Society, American Public Health Association, Association of Professors of Gynecology and Obstetrics, Perinatal Research Society, Phi Beta Kappa, Society for Gynecologic Investigation, Society for Maternal-Fetal Medicine, and Society for Neuroscience
Disclosure: Nothing to disclose.

Medical Editor

Bruce A Meyer, MD, MBA, Vice President for Medical Affairs, Associate Dean for Health System Affairs and Director of the Faculty Practice Plan, Professor, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical School
Bruce A Meyer, MD, MBA is a member of the following medical societies: American College of Obstetricians and Gynecologists, American College of Physician Executives, American Institute of Ultrasound in Medicine, Association of Professors of Gynecology and Obstetrics, Massachusetts Medical Society, Medical Group Management Association, and Society for Maternal-Fetal Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Antonio V Sison, MD, Medical Director, Ob/Gyn Group, Robert Wood Johnson University Hospital at Hamilton
Antonio V Sison, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists and Association of Professors of Gynecology and Obstetrics
Disclosure: Nothing to disclose.

CME Editor

Frederick B Gaupp, MD, Consulting Staff, Department of Family Practice, Hancock Medical Center
Frederick B Gaupp, MD is a member of the following medical societies: American Academy of Family Physicians
Disclosure: Nothing to disclose.

Chief Editor

David Chelmow, MD, Professor of Obstetrics and Gynecology, Tufts University School of Medicine; Program Director, Tufts University Affiliated Hospitals OB/GYN Residency Program; Chair, Tufts University Health Sciences Campus Institutional Review Board; Vice Chair for Research and Education, Dept of OB/GYN, Tufts Medical Center
David Chelmow, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, American Medical Association, Association of Professors of Gynecology and Obstetrics, Massachusetts Medical Society, Phi Beta Kappa, Sigma Xi, Society for Gynecologic Investigation, and Society for Medical Decision Making
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.